May 13th 2024
The submission for bevacizumab gamma (ONS-5010/LYTENAVA) follows a positive opinion from the CHMP in March
(COPE Credit) Community Practice Connection™: Paradigm Shifts in Presbyopia – Understanding Advances in Topical Treatment Innovations
View More
(CME Credit) Learning About the Lid – Optimizing Recognition, Diagnosis, and Treatment of Demodex Blepharitis & Blepharoptosis
View More
2nd Annual IKA Keratoconus Symposium: Front to Back and Everything in Between
May 18-19, 2024
Register Now!
(COPE Credit) Learning About the Lid – Optimizing Recognition, Diagnosis, and Treatment of Demodex Blepharitis & Blepharoptosis
View More
(COPE Credit) Clinical Crossroads: Navigating Neurotrophic Keratitis – The Importance of Avoiding Pitfalls and Ensuring Early Intervention
View More
(CME Credit) Virtual Case Studies™ in Cataract Surgery: Selecting Surgical Techniques and Preventing Intra-Operative Complications
View More
Neurotrophic Keratitis Management: How Early Intervention Can Make a Difference
View More
(CME Credit) Clinical Crossroads: Navigating Neurotrophic Keratitis – The Importance of Avoiding Pitfalls and Ensuring Early Intervention
View More
17th Annual Controversies in Modern Eye Care
View More
Thyroid Eye Disease: The Masquerading Eye Disorder—A Guide to Collaborative Care and Accurate Diagnosis
View More
(COPE Credit) Community Practice Connections™: Advances in Geographic Atrophy – Optimizing Diagnosis, Monitoring Progression, and Increasing Communication with Transformative Treatment on the Horizon
View More
(CME Credit) Community Practice Connections™: Multidisciplinary Perspectives on Saving Sight—The Expanding Role of the Optometrist in Retinal Disease Care
View More
(CME Credit) Community Practice Connections™: Advances in Geographic Atrophy – Optimizing Diagnosis, Monitoring Progression, and Increasing Communication with Transformative Treatment on the Horizon
View More
(COPE Credit) Community Practice Connections™: Keeping an Eye on Evolving Management Strategies for nAMD and DME
View More
(COPE Credit) Community Practice Connections™: Multidisciplinary Perspectives on Saving Sight—The Expanding Role of the Optometrist in Retinal Disease Care
View More
(CME Credit) Community Practice Connections™: Keeping an Eye on Evolving Management Strategies for nAMD and DME
View More
The Ins and Outs of Lubricating Eye Drops
View More
What’s New in MGD Beyond Heating and Squeezing?
View More
Addressing Healthcare Inequities™ in Glaucoma Management – Understanding Challenges in Segmented Patient Populations (CME Track)
View More
Community Practice Connections™: Expert Perspectives in Diabetic Macular Edema – Considering Pathogenesis & Inflammation in Treatment Selection
View More
Community Practice Connections™: Novel Treatment Strategies in the Management of nAMD & DME - Lessons from Clinical Trial and Real-World Data
View More
Medical Crossfire®: Considerations for the Use of Biosimilars in Retinal Disease - Are You Prepared for a New Paradigm? (CME Credit)
View More
Medical Crossfire®: Expert Insights in Anti-VEGF Dosing for nAMD and DME – Optimizing Reduction in Treatment Burden
View More
Medical Crossfire®: Considerations for the Use of Biosimilars in Retinal Disease - Are You Prepared for a New Paradigm? (COPE Credit)
View More
EyeCon 2024
September 27-28, 2024
Register Now!
Heading to AAO? You’re invited to a CME dinner. Or join virtually!
Date TBA
Register Now!
(CME) Community Practice Connections™: A Closer Look at Neurotrophic Keratitis—Ensuring Timely Diagnosis and Taking Early Action
View More
Community Practice Connections™: Mastering the Multidisciplinary Management of Glaucoma—Understanding Advances in the Spectrum of Treatment Innovation (CME/CNE Credit)
View More
(COPE) Community Practice Connections™: A Closer Look at Neurotrophic Keratitis—Ensuring Timely Diagnosis and Taking Early Action
View More
Community Practice Connections™: Mastering the Multidisciplinary Management of Glaucoma—Understanding Advances in the Spectrum of Treatment Innovation (COPE Credit)
View More
Spectral-domain optical coherence tomography represents step forward
April 30th 2008Spectral domain, three-dimensional (3-D), high-resolution optical coherence tomography (OCT) represents a step forward in OCT technology, with precise registration, complete data set acquisition, and improved coverage of the retina being the major advantages.
Breakthrough in understanding vascular biology may lead to safer and more effective anti-angiogenics
April 30th 2008VEGFb, a novel form of vascular endothelial growth factor (VEGF), an anti-angiogenic which is cytoprotective for retinal cells, can inhibit choroidal neovascularization significantly, according to preclinical results presented at this year's BIO National Venture Conference, held April 22?23 in Cambridge, US.
FDA approves expansion of NeoVista's Phase III CABERNET trial
April 23rd 2008The FDA has approved an expansion of the Phase III CABERNET (CNV Secondary to AMD Treated with BEta RadiatioN Epiretinal Therapy) trial, which is evaluating the safety and efficacy of NeoVista's epiretinal brachytherapy in wet age-related macular degeneration (AMD).
Human embryonic stem cells have potential to treat retinal degeneration
April 16th 2008Regeneration of damaged retinal cells with the aid of stem cells may offer hope for the treatment of retinal degeneration conditions, such as age-related macular degeneration (AMD) and diabetic retinopathy (DR), according to a report published by the National Academy of Sciences (Volume 103).
AMD linked to increased incidence of death from stroke, cardiovascular events
April 16th 2008Age-related macular degeneration (AMD) may be a useful indicator for predicting death from stroke or cardiovascular disease, according to a study published online ahead of print by the British Journal of Ophthalmology.
Phase II trial shows epiretinal brachytherapy + bevacizumab improves VA
April 9th 2008NeoVista Inc?s epiretinal brachytherapy for wet AMD in combination with Avastin (bevacizumab) has been shown to improve mean visual acuity (VA) in patients, with adverse events restricted to vitrectomy-related problems and not to radiation toxicity, according to results of a Phase II trial presented at the 31st Annual Macula Society Meeting in Palm Beach, Florida, US.
Lucentis to be made available to all in England and Wales
April 9th 2008Lucentis (ranibizumab; Novartis) is to be made available to all patients of the National Health Service (NHS) in England and Wales, according to a report from the BBC. The final appraisal document (FAD) has been published ahead of final guidance, expected in June 2008.
Preop antibiotics may not be needed to prevent endophthalmitis after intravitreal steroid use
April 9th 2008A low rate of endophthalmitis can be achieved after intravitreal triamcinolone injection without the use of antibiotic prophylaxis on the pretreatment days, said Abdhish R. Bhavsar, MD, at the annual meeting of the American Society of Retina Specialists.
Injection-related complications revealed
April 2nd 2008Injection-related complications such as infectious endophthalmitis, retinal detachment, and traumatic cataract may occur with a frequency of about 0.15% after intravitreal injections of bevacizumab or triamcinolone, independently of the drug injected, according to a study published in the February issue of Eye.
Shorter laser exposure just as effective as the conventional approach
April 2nd 2008Shortening of retinal laser exposure time is just as effective as conventional, longer laser exposure in patients undergoing laser photocoagulation, but is significantly less painful, according to a study published in the January issue of Eye.
Office safer than the operating theatre for intravitreal injections
March 26th 2008The incidence of endophthalmitis following injections of anti-VEGF drugs is lower when the injections are given in an office setting than the rates reported from clinical trials, which require a more extensive pre-injection regimen.
Periocular injection a feasible route for CNV treatment
March 19th 2008The size and binding characteristics of proteins are likely to influence their ability to penetrate the eye from the periocular space, but in general, proteins as large as 50-75 kDa penetrate well into the choroid but not into the retina.
Fewer Lucentis injections with new regimen
March 12th 2008Preliminary results of a study using the NSAID Xibrom (bromfenac ophthalmic solution 0.09%; ISTA Pharmaceuticals) therapy in combination with Lucentis (ranibizumab; Novartis) in patients with wet age-related macular degeneration (AMD), suggests that it may result in fewer injections being required.